Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Inclusion Criteria: * Patients 18 years of age or older with evidence of relapsed or refractory disease as defined by IMWG criteria and measurable disease as defined by any of the following: * Serum M-protein ≥ 0.5 g/dl * Urine monoclonal protein ≥ 200 mg/24h * Involved free light chain (FLC) level ≥ 10mg/dl (≥ 100mg/l) and an abnormal serum free light chain ratio (\< 0.26, or \> 1.65) * Patients must have had at least 4 prior lines of therapy including an immunomodulatory agent (IMID), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. * Prior B-cell maturating antigen (BCMA) chimeric antigen receptor (CAR)-T is permitted but at least 6 months must have lapsed from CAR-T exposure * Prior tumor necrosis factor alpha (TNFα) inhibitor use for a concomitant condition (ex. Rheumatoid arthritis) is permitted but at least 6 months must have lapsed from exposure * Patients must have hemoglobin ≥ 7g/dL * Absolute neutrophil count (ANC) ≥ 1000/µL * Platelets ≥ 50,000/µL * Total bilirubin ≤ 1.5 X the upper limit of normal (ULN) * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \< 2.5 X the ULN * Calculated creatinine clearance of ≥ 30ml/min using Modification of Diet in Renal Disease (MDRD) formula * Patients must have adequate cardiac function as evidenced by: * Left ventricular ejection fraction ≥ 30%; baseline echocardiography (ECHO) is not required if ECHO was done within the preceding 6 months and patients do not have new signs/symptoms suggestive of heart failure * No uncontrolled arrhythmias * No New York Heart Association class III-IV heart failure * 12-lead electrocardiogram (ECG) with QT interval calculated by Fridericia Formula (QTcF) interval of ≤ 470 msec * Negative test result for latent tuberculosis at screening * Patients must provide informed consent * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤ 2 * Fertility requirements * Women of child bearing potential (WOCBP) must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device \[IUD\], hormonal \[birth control pills, injections, hormonal patches, vaginal rings or implants\] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin 4 weeks prior to dosing and continue to 6 months after study treatment ending or teclistamab/talquetamab ending, whichever is longer. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy * Investigators shall counsel WOCBP and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy * A negative pregnancy test will be required for all WOCBP at screening and within 24 hours before starting treatment drugs, and with each cycle * Breast feeding is not permitted * Male patients must agree to use an adequate method of contraception (latex or synthetic condom) for the duration of the study and up to 6 months after study treatment ending * Criteria also applies to azoospermic males * Males should refrain from sperm donation during this time and continue for 6 months after study treatment ending Exclusion Criteria: * Patients with Waldenstrom macroglobulinemia, primary amyloid light chain (AL) amyloidosis, primary plasma cell leukemia, or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome * Patients receiving concurrent corticosteroids at the time protocol therapy is initiated other than for physiologic maintenance treatment * Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs * Live vaccines should not be given concurrently with infliximab. Vaccination with live virus vaccines is not recommended for at least 4 weeks prior to the start of treatment, during treatment and least 4 weeks after treatment * Clinically active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and/or ankylosing spondylitis (AS), or concurrent use of abatacept, anakinra, rituximab, or other biologic products approved to treat these diseases within the preceding 6 months * Patients with history of anaphylaxis or hypersensitivity to etanercept, infliximab, adalimumab, certolizumab pegol, or golimumab * Unacceptable respiratory risk factors defined by any one of the following criteria: * Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than 50% of predicted normal * Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification * Unacceptable cardiac risk factors defined by any of the following criteria: * Left ventricular ejection fraction \< 30% * Complete left bundle branch, bifascicular block or clinically significant abnormal electrocardiogram (EKG) finding at screening * A prolongation of QT interval on Screening ECG as defined by repeated demonstration of a QTc interval \> 470 msec using Fridericia's QT correction formula; a family history of Long QT Syndrome * Myocardial infarction within 6 months * Unstable angina * Unacceptable infectious risk factors defined by any of the following criteria: * Active tuberculosis: * History of active or latent tuberculosis (TB) before screening * Any signs or symptoms suggestive of active TB upon medical history and/or physical examination * Any known recent close contact with a person with active TB. * Active invasive fungal infections * Other active infections, including clinically important localized infections, and patients with a